Vilya Expands Series A Financing to $71 Million to Advance Computational Drug Design and Develop a New Class of Medicines
“This funding also extends our ability to rapidly advance our designed macrocycles to clinical development candidates.”
- “This funding also extends our ability to rapidly advance our designed macrocycles to clinical development candidates.”
Vilya's foundational technology leverages advanced computational approaches to design novel macrocycles with atomic-level accuracy and enhanced drug-like properties. - With Vilya’s technology, the Company can precisely target disease biology in areas where innovative treatment approaches for patients are still needed.
- According to Yap, “Vilya places groundbreaking AI technology in the hands of experienced drug developers to open up this valuable but difficult drug class.
- The Company is building a world-class team with deep expertise in computational drug discovery that complements its extensive experience across drug design, chemistry, biology and clinical and corporate development.